FDA Grants Traditional Approval to Tarlatamab-dlle for Extensive Stage Small Cell Lung Cancer By Ogkologos - January 22, 2026 426 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the DeLLphi-304 study Source RELATED ARTICLESMORE FROM AUTHOR Perioperative Pembrolizumab Plus Neoadjuvant Chemotherapy Continues to Prolong EFS and OS in Patients with Stage II, IIIA, or IIIB (N2) NSCLC Patient Guide in Soft Tissue Sarcoma Now Available Also in Ukrainian Adjuvant Pembrolizumab Continues to Demonstrate Benefit in DFS and OS Among Patients with ccRCC MOST POPULAR FDA Grants Accelerated Approval to Repotrectinib for Adult and Paediatric Patients... July 8, 2024 FDA Grants Accelerated Approval to Selpercatinib for Paediatric Patients Two Years... June 18, 2024 Επικοινωνία January 18, 2019 FDA Approves Dostarlimab-gxly with Chemotherapy for Endometrial Cancer August 11, 2023 Load more HOT NEWS FDA Grants Accelerated Approval to Selpercatinib for Paediatric Patients Two Years... EMA Recommends Granting a Marketing Authorisation for Piflufolastat (18F) Cancer “Liquid Biopsy” Blood Test Gets Expanded FDA Approval ΠΟΝΟΣ
